SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001567619-20-017872
Filing Date
2020-10-15
Accepted
2020-10-15 17:17:09
Documents
1
Period of Report
2020-10-15

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 12765
  Complete submission text file 0001567619-20-017872.txt   15323
Mailing Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301
Business Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301 650 688 0818
Vivo Capital Fund VIII, L.P. (Reporting) CIK: 0001618788 (see all company filings)

Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39617 | Film No.: 201242123

Mailing Address 192 LYTTON AVENUE PALO ALTO CA 94301
Business Address 192 LYTTON AVENUE PALO ALTO CA 94301 650 688 0822
Vivo Capital VIII, LLC (Reporting) CIK: 0001618789 (see all company filings)

Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39617 | Film No.: 201242122

Mailing Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301
Business Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301 650 688 0818
Vivo Capital Surplus Fund VIII, L.P. (Reporting) CIK: 0001628048 (see all company filings)

Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39617 | Film No.: 201242124

Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Issuer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences